These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27389877)

  • 21. Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.
    Janovick JA; Brothers SP; Cornea A; Bush E; Goulet MT; Ashton WT; Sauer DR; Haviv F; Greer J; Conn PM
    Mol Cell Endocrinol; 2007 Jun; 272(1-2):77-85. PubMed ID: 17555869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. V2R mutations and nephrogenic diabetes insipidus.
    Bichet DG
    Prog Mol Biol Transl Sci; 2009; 89():15-29. PubMed ID: 20374732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
    Los EL; Deen PM; Robben JH
    J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism.
    de la Nuez Veulens A; Ginarte YMÁ; Fernandez RER; Leclerc F; Cabrera LAM
    J Mol Model; 2022 Jan; 28(2):31. PubMed ID: 34997307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.
    Janovick JA; Stewart MD; Jacob D; Martin LD; Deng JM; Stewart CA; Wang Y; Cornea A; Chavali L; Lopez S; Mitalipov S; Kang E; Lee HS; Manna PR; Stocco DM; Behringer RR; Conn PM
    Proc Natl Acad Sci U S A; 2013 Dec; 110(52):21030-5. PubMed ID: 24324164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.
    Bernier V; Lagacé M; Lonergan M; Arthus MF; Bichet DG; Bouvier M
    Mol Endocrinol; 2004 Aug; 18(8):2074-84. PubMed ID: 15166253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation.
    Tan CM; Nickols HH; Limbird LE
    J Biol Chem; 2003 Sep; 278(37):35678-86. PubMed ID: 12824183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders.
    Hou ZS; Ulloa-Aguirre A; Tao YX
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):611-624. PubMed ID: 29851355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH; Sze M; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of pharmacochaperone-mediated rescue of mutant V2 receptor proteins.
    Erdem Tuncdemir B; Mergen H; Saglar Ozer E
    Eur J Pharmacol; 2019 Dec; 865():172803. PubMed ID: 31738937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.
    Ratni H; Rogers-Evans M; Bissantz C; Grundschober C; Moreau JL; Schuler F; Fischer H; Alvarez Sanchez R; Schnider P
    J Med Chem; 2015 Mar; 58(5):2275-89. PubMed ID: 25654260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.
    Conn PM; Smith E; Spicer T; Chase P; Scampavia L; Janovick JA
    Assay Drug Dev Technol; 2014 May; 12(4):238-46. PubMed ID: 24831790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolvaptan-Type Vasopressin Receptor Ligands: Important Role of Axial Chirality in the Active Form.
    Tabata H; Yoneda T; Oshitari T; Takahashi H; Natsugari H
    J Med Chem; 2017 May; 60(10):4503-4509. PubMed ID: 28475329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).
    Ślusarz MJ
    Expert Opin Ther Pat; 2015 Jun; 25(6):711-22. PubMed ID: 25776143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking.
    Tiulpakov A; White CW; Abhayawardana RS; See HB; Chan AS; Seeber RM; Heng JI; Dedov I; Pavlos NJ; Pfleger KD
    Mol Endocrinol; 2016 Aug; 30(8):889-904. PubMed ID: 27355191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
    Robben JH; Deen PM
    BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus.
    Faerch M; Christensen JH; Rittig S; Johansson JO; Gregersen N; de Zegher F; Corydon TJ
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1518-25. PubMed ID: 19812297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist.
    Rihakova L; Quiniou C; Hamdan FF; Kaul R; Brault S; Hou X; Lahaie I; Sapieha P; Hamel D; Shao Z; Gobeil F; Hardy P; Joyal JS; Nedev H; Duhamel F; Beauregard K; Heveker N; Saragovi HU; Guillon G; Bouvier M; Lubell WD; Chemtob S
    Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1009-18. PubMed ID: 19641130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients.
    Gitelman SE; Feldman BJ; Rosenthal SM
    Am J Med; 2006 Jul; 119(7 Suppl 1):S54-8. PubMed ID: 16843086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.